News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
730,152 Results
Type
Article (41330)
Company Profile (265)
Press Release (688540)
Multimedia
Podcasts (91)
Webinars (20)
Section
Business (204836)
Career Advice (2032)
Deals (35579)
Drug Delivery (128)
Drug Development (81508)
Employer Resources (173)
FDA (16503)
Job Trends (14980)
News (346797)
Policy (32750)
Tag
2027 BioCapital Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (5)
Academia (2593)
Accelerated approval (46)
Adcomms (26)
Allergies (170)
Alliances (49579)
ALS (210)
Alzheimer's disease (1782)
Antibody-drug conjugate (ADC) (440)
Approvals (16875)
Artificial intelligence (650)
Autoimmune disease (280)
Automation (54)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (219)
Biotechnology (175)
Bladder cancer (186)
Brain cancer (70)
Breast cancer (743)
Cancer (5753)
Cardiovascular disease (466)
Career advice (1724)
Career pathing (41)
CAR-T (327)
CDC (56)
Celiac Disease (3)
Cell therapy (884)
Cervical cancer (47)
Clinical research (70733)
Collaboration (2032)
Company closure (5)
Compensation (1380)
Complete response letters (78)
COVID-19 (2740)
CRISPR (107)
C-suite (1105)
Cystic fibrosis (151)
Data (7750)
Decentralized trials (3)
Denatured (27)
Depression (159)
Dermatology (83)
Diabetes (584)
Diagnostics (6915)
Digital health (54)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (313)
Drug pricing (200)
Drug shortages (31)
Duchenne muscular dystrophy (280)
Earnings (91893)
Editorial (66)
Employer branding (21)
Employer resources (152)
Events (119346)
Executive appointments (1075)
FDA (20191)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (15)
Frontotemporal dementia (34)
Funding (1703)
Gene editing (232)
Generative AI (55)
Gene therapy (712)
GLP-1 (1049)
Government (4728)
Grass and pollen (6)
Guidances (408)
Healthcare (18986)
HIV (79)
Huntington's disease (56)
IgA nephropathy (96)
Immunology and inflammation (285)
Immuno-oncology (91)
Indications (188)
Infectious disease (3077)
Inflammatory bowel disease (216)
Inflation Reduction Act (14)
Influenza (136)
Intellectual property (288)
Interviews (319)
IPO (16666)
IRA (50)
Job creations (3647)
Job search strategy (1431)
JPM (58)
Kidney cancer (19)
Labor market (98)
Layoffs (562)
Leadership (38)
Legal (7953)
Liver cancer (99)
Longevity (32)
Lung cancer (757)
Lymphoma (426)
Machine learning (59)
Management (59)
Manufacturing (1028)
MASH (183)
Medical device (13918)
Medtech (14035)
Mergers & acquisitions (20152)
Metabolic disorders (1484)
mRNA (203)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (411)
Neuropsychiatric disorders (105)
Neuroscience (3278)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4530)
Now hiring (77)
Obesity (695)
Opinion (285)
Ovarian cancer (218)
Pain (250)
Pancreatic cancer (294)
Parkinson's disease (356)
Partnered (33)
Patents (592)
Patient recruitment (665)
Peanut (62)
People (59540)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (22047)
Phase 2 (31159)
Phase 3 (23191)
Pipeline (8446)
Policy (313)
Postmarket research (2568)
Preclinical (9391)
Press Release (64)
Prostate cancer (293)
Psychedelics (54)
Radiopharmaceuticals (319)
Rare diseases (1063)
Real estate (5968)
Recruiting (70)
Regulatory (25355)
Reports (56)
Research institute (2412)
Resumes & cover letters (353)
Rett syndrome (38)
RNA editing (21)
RSV (88)
Schizophrenia (176)
Series A (286)
Series B (210)
Service/supplier (11)
Sickle cell disease (111)
Special edition (23)
Spinal muscular atrophy (165)
Sponsored (48)
Startups (3638)
State (2)
Stomach cancer (18)
Supply chain (126)
Tariffs (87)
The Weekly (62)
Vaccines (1088)
Venture capital (107)
Weight loss (447)
Women's health (124)
Worklife (20)
Date
Today (213)
Last 7 days (934)
Last 30 days (3415)
Last 365 days (30205)
2026 (11901)
2025 (30170)
2024 (35211)
2023 (40072)
2022 (51175)
2021 (55707)
2020 (54081)
2019 (46537)
2018 (35016)
2017 (32107)
2016 (31479)
2015 (37551)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (741)
Alabama (92)
Alaska (7)
Arizona (347)
Arkansas (14)
Asia (39644)
Australia (6499)
California (13120)
Canada (3725)
China (1322)
Colorado (562)
Connecticut (571)
Delaware (400)
Europe (85779)
Florida (1961)
Georgia (420)
Hawaii (3)
Idaho (62)
Illinois (1044)
India (88)
Indiana (596)
Iowa (23)
Japan (529)
Kansas (130)
Kentucky (50)
Louisiana (40)
Maine (75)
Maryland (1576)
Massachusetts (9365)
Michigan (358)
Minnesota (707)
Mississippi (6)
Missouri (143)
Montana (33)
Nebraska (29)
Nevada (140)
New Hampshire (84)
New Jersey (3452)
New Mexico (29)
New York (3430)
North Carolina (1663)
North Dakota (9)
Northern California (6567)
Ohio (393)
Oklahoma (23)
Oregon (41)
Pennsylvania (2637)
Puerto Rico (29)
Rhode Island (50)
South America (1112)
South Carolina (85)
South Dakota (2)
Southern California (5174)
Tennessee (209)
Texas (2084)
United States (46297)
Utah (392)
Vermont (1)
Virginia (316)
Washington D.C. (80)
Washington State (1051)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
730,152 Results for "atreca inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Immunome Announces Completion of Purchase of Assets from Atreca
Immunome, Inc. today announced the completion of its purchase of antibodies and related assets from Atreca, Inc.
May 20, 2024
·
4 min read
Deals
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
Immunome, Inc. announced that it entered into a definitive asset purchase agreement with Atreca, Inc. to acquire a collection of antibody-related assets and materials.
December 26, 2023
·
4 min read
Biotech Bay
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
Atreca, Inc. announced that it entered into a definitive asset purchase agreement with Immunome, Inc. to sell a collection of antibody-related assets and materials.
December 26, 2023
·
7 min read
Business
Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments
Atreca, Inc. (Atreca) (NASDAQ: BCEL) today announced financial results for the first quarter ended March 31, 2023 and provided an overview of recent developments.
May 10, 2023
·
5 min read
Business
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
Atreca, Inc. announced financial results for the second quarter ended June 30, 2023, and announced a corporate reorganization to reduce expenses and extend its cash runway.
August 10, 2023
·
7 min read
Business
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
Atreca, Inc. reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary support to continue exploring potential strategic transactions and business alternatives.
November 14, 2023
·
5 min read
Business
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
Atreca, Inc. announced that, as part of its ongoing efforts to lower operating expenses, the Company has entered into an agreement to terminate its lease agreement pertaining to the Company’s headquarters in San Carlos, CA, which represented approximately $13 million of annual expenditures.
September 21, 2023
·
4 min read
Business
Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update
Atreca, Inc. (Atreca) (NASDAQ: BCEL) today announced financial results for the fourth quarter and full-year ended December 31, 2022, and provided an overview of recent developments.
March 29, 2023
·
13 min read
Biotech Bay
Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
Atreca, Inc. today announced that John A. Orwin, President and Chief Executive Officer, will be participating in a panel discussion on T-Cells and “Informative B-Cells” at the Canaccord Genuity Horizons in Oncology Virtual Conference.
April 13, 2023
·
2 min read
Business
Atreca Appoints Philippe Bishop, MD as Chief Medical Officer
Atreca, Inc. announced the appointment of Philippe Bishop, MD, as Chief Medical Officer, effective immediately.
January 9, 2023
·
5 min read
1 of 73,016
Next
